The Life Sciences team advised HOOKIPA Pharma on the completion of its $37.4 million (€33.2 million) Series D financing which was led by Redmile Group with participation of additional new investors Invus and Samsara BioCapital, as well as a number of current investors.
The new funding will be primarily used to progress the clinical development of HOOKIPA’s lead development programs, HB-101, a prophylactic cytomegalovirus vaccine candidate, currently in a Phase 2 clinical trial in patients awaiting kidney transplantation as well as HB-201 and HB-202, HOOKIPA’s lead oncology product candidates, in development for the treatment of human papillomavirus-positive cancers.
Based in Vienna, Austria and New York, HOOKIPA is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.
The Goodwin team was led by partner Robert Puopolo and associate Timothy Hurley.